Zelboraf Pricing In Germany Still Tied Up By Crossover Trial Design
This article was originally published in The Pink Sheet Daily
IQWiG reiterates its “considerable added benefit” rating for the melanoma drug, but pricing negotiations will reopen in 2014.
You may also be interested in...
NICE has recommended Roche’s Zelboraf and BMS’ Yervoy, as expected based partly on undeniable life extension capabilities, but also on secret price discounts offered by both manufacturers.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.